Association Between Reduced Levels of Alkaline Phosphatase and Survival Times of Patients With Primary Sclerosing Cholangitis Lina Lindström, Rolf Hultcrantz, Kirsten Muri Boberg, Ingalill Friis–Liby, Annika Bergquist Clinical Gastroenterology and Hepatology Volume 11, Issue 7, Pages 841-846 (July 2013) DOI: 10.1016/j.cgh.2012.12.032 Copyright © 2013 AGA Institute Terms and Conditions
Figure 1 Kaplan–Meier survival curve of 198 patients enrolled in the 5-year Scandinavian UDCA trial in 1996 randomized to UDCA vs placebo with extended follow-up in 2009/2010 (P = .77, log-rank test). Clinical Gastroenterology and Hepatology 2013 11, 841-846DOI: (10.1016/j.cgh.2012.12.032) Copyright © 2013 AGA Institute Terms and Conditions
Figure 2 Kaplan–Meier analysis of end point–free survival in UDCA-treated patients with a biochemical response (ie, normal or ≥40% reduction in ALP after 1 year in the trial) vs nonresponders (P = .033, log-rank test). Clinical Gastroenterology and Hepatology 2013 11, 841-846DOI: (10.1016/j.cgh.2012.12.032) Copyright © 2013 AGA Institute Terms and Conditions
Figure 3 Kaplan–Meier analysis of end point–free survival in biochemical responders vs nonresponders, regardless of treatment with UDCA (P = .0001, log-rank test). Clinical Gastroenterology and Hepatology 2013 11, 841-846DOI: (10.1016/j.cgh.2012.12.032) Copyright © 2013 AGA Institute Terms and Conditions
Figure 4 Kaplan–Meier analysis of end point–free survival in all patients stratified by treatment with UDCA and biochemical response (P = .001, log-rank test). Clinical Gastroenterology and Hepatology 2013 11, 841-846DOI: (10.1016/j.cgh.2012.12.032) Copyright © 2013 AGA Institute Terms and Conditions